期刊文献+

Taxus与Cypher洗脱支架冠脉置人术对患者CRP及MMP-9的影响

原文传递
导出
摘要 目的评价紫杉醇和雷帕霉素两种洗脱支架冠状动脉置入术对患者c反应蛋白(CRP)及基质金属蛋白酶-9(MMP-9)的影响及临床应用价值。方法入选83例Braunwald分级ⅡB级的不稳定心绞痛患者,分成紫杉醇药物洗脱支架组(紫杉醇组,美国Boston公司Taxus支架)41例(43个病变)和雷帕霉素药物洗脱支架组(雷帕霉素组,美国Cordis公司Cypher支架)42例(45个病变)。进行择期冠状动脉腔内药物洗脱支架置入术。于术前、术后2h、术后1周留取血清样本应用免疫透射比浊法测定CRP水平,保存血清样本于~75℃冰箱冻存,应用酶联免疫分析法测定MMP-9水平。结果78例患者成功置入药物洗脱支架,术前、术后2h、术后1周血清总CRP水平分别为(9.5±3.8)、(11.8±5.6)、(22.8±11.2)mg/dl(P〈0.05),血清总MMP-9水平分别为(49.66±2.64)、(52.1±2.45)、(89.76±2.58)ng/ml(P〈0.05)。进一步进行亚组分析,37例置入Taxus支架与41例置入Cypher支架的患者CRP与MMP.9水平差异无统计学意义(P〉0.05)。结论药物洗脱支架置入术后CPR与MMP-9水平逐渐升高,两者具有一定的相关性;CRP与MMP-9均可作为冠状动脉支架置入术后炎症反应强弱的指标。本组患者Taxus支架与Cypher支架对CRP与MMP-9的影响差异无统计学意义。
出处 《中国医师杂志》 CAS 2009年第6期840-841,共2页 Journal of Chinese Physician
  • 相关文献

参考文献7

  • 1Sundstrom J,Evans JC, Benjamin E J, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures:the Framingham Heart Study. Circulation,2004,109 (23) :2850-2856.
  • 2Nomoto K, Oguchi S, Watanabe I, et al. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein,matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1. J Cardiol,2003 ,42 :201-206.
  • 3Pepys MB, Hirschfleld GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature, 2006, 440 : 1217-1221.
  • 4Armstrong E J, Morrow DA, Sabatine MS. Inflammatory Biomarkers in Acute Coronary Syndromes: Part Ⅳ:Matrix Metalloproteinases and Biomarkers of Platelet Activation. Circulation, 2006,113:382-385.
  • 5Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res,2002,91 (9) :852-859.
  • 6Eclart R, Uyehara C, Shry E, et al. Matrix metalloproteinases in patients with myocardial intarction and percutaneous revascularization. J Interv Cardiol,2004,17:27-31.
  • 7Blankenberg S, Rupprecht HJ, Poirier O, et al. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinases 9 and prognosis of patients with cardiovascular disease. Circulation ,2003,107 : 1579-1585.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部